This trial compares sentinel lymph node mapping vs. standard lymph node dissection to reduce risk of leg swelling in patients undergoing hysterectomy for stage I endometrial cancer.
- Stage I Uterine Corpus Cancer
1 Primary · 2 Secondary · Reporting Duration: From enrollment and at 3, 6, 9, 12, and 18 months after surgery.
2 Treatment Groups
Arm 2 (sentinel lymph node mapping, pelvic lymphadenectomy)
1 of 2
Arm 1 (sentinel lymph node mapping)
1 of 2
428 Total Participants · 2 Treatment Groups
Primary Treatment: Arm 2 (sentinel lymph node mapping, pelvic lymphadenectomy) · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · Female Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any more opportunities for participants to join this clinical experiment?
"According to clinicaltrials.gov, this research endeavor is still enrolling participants. It was initially published on September 19th 2022 and underwent the latest revision on December 2nd 2022. The study necessitates 428 individuals at a solitary site for completion." - Anonymous Online Contributor
Has the sentinel lymph node mapping technique attained FDA approval?
"Our team evaluated the safety of Arm 1 (sentinel lymph node mapping) to be a 3 due to existing evidence from Phase 3 trials that suggest it is both efficacious and safe." - Anonymous Online Contributor
How many participants are recruited for this research?
"Affirmative. On clinicaltrials.gov, it is stated that this research project began recruitment on September 19th 2022 and was recently updated December 2nd of the same year. The aim is to gather 428 study participants from a single medical site." - Anonymous Online Contributor